Literature DB >> 19481004

Infectious complications of biologic agents.

Emilio Martin-Mola1, Alejandro Balsa.   

Abstract

Infection is a frequent complication in rheumatoid arthritis (RA) and other autoimmune diseases. Since 2000, the spectrum of therapeutic possibilities (ie, biologic agents) for treating RA has expanded rapidly and many safety reports of patients treated with these drugs have been published. In most studies, biologics are associated with an increased incidence of infections with the use of tumor necrosis factor antagonists. Reported risks for developing infection differ among studies. This article provides an overview of which studies the authors consider the most relevant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481004     DOI: 10.1016/j.rdc.2009.03.009

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  17 in total

1.  Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?

Authors:  László Maródi; Jean-Laurent Casanova
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs.

Authors:  Martina Maritati; Alessandro Trentini; Gregory Michel; Tiziana Bellini; Shawgi Almugadam; Stefania Hanau; Marcello Govoni; Pierre Marty; Carlo Contini
Journal:  Infection       Date:  2018-08-10       Impact factor: 3.553

3.  Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Ronald H B Meyboom; Sabine M J M Straus; Hubert G M Leufkens; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

4.  Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015.

Authors:  Mengqin Ge; Kenneth K Man; Celine S Chui; Esther W Chan; Ian C Wong; Xue Li
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

5.  Cutaneous leishmaniasis associated with TNF-α blockers: a case report.

Authors:  Pelayo Nieto Gómez; Inmaculada Casas Hidalgo; María de la Paz Casas Hidalgo; Raquel Álvarez Sánchez; Alejandro Rodríguez Delgado; Jose Cabeza-Barrera
Journal:  Eur J Hosp Pharm       Date:  2018-05-05

Review 6.  Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.

Authors:  Sima S Toussi; Nancy Pan; Heather M Walters; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-07-29       Impact factor: 9.079

7.  Outcomes of immunomodulatory and biologic therapy in people living with HIV.

Authors:  Michael J Peluso; Jessica Chen; Sadie Munter; Asia Reed; Justin Teraoka; Ingrid Eshun-Wilson; Timothy J Henrich; Peter V Chin-Hong
Journal:  AIDS       Date:  2020-07-01       Impact factor: 4.177

Review 8.  Vaccinations in patients with immune-mediated inflammatory diseases.

Authors:  Jean-François Rahier; Michel Moutschen; Alfons Van Gompel; Marc Van Ranst; Edouard Louis; Siegfried Segaert; Pierre Masson; Filip De Keyser
Journal:  Rheumatology (Oxford)       Date:  2010-06-29       Impact factor: 7.580

9.  Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.

Authors:  Yingjuan Lu; Torian W Stinnette; Elaine Westrick; Patrick J Klein; Mark A Gehrke; Vicky A Cross; Iontcho R Vlahov; Philip S Low; Christopher P Leamon
Journal:  Arthritis Res Ther       Date:  2011-04-04       Impact factor: 5.156

10.  Listeria meningitis and resultant symptomatic hydrocephalus complicating infliximab treatment for ulcerative colitis.

Authors:  Fahd Rana; Muddassir Muhammad Shaikh; Jane Bowles
Journal:  JRSM Open       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.